This is a working overview of Reverse-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-27. Anything still debated is marked as such rather than presented as settled.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
American history does not distinguish between civilians and military, not even women and children. They are the ones who used [a nuclear bomb] against Nagasaki. Can these bombs distinguish between infants and military? America does not have a religion that will prevent it from destroying all people. So we tell the Americans as people [...] that if they value their lives and the lives of their children, to find a nationalist government that will look after their interests and not the interests of the Jews. After 9/11, bin Laden maintained that women and children were not targeted in the attack—rather, symbols of America's "economic and military power." In December 2001, a video of bin Laden was released in which he did not admit responsibility for 9/11, but instead said:
The second tier consists of several dozens of midsized companies, with sales in the range of $100–$250 million per year. Their portfolios comprise both custom manufacturing and API-for-generics. They include both independents and subsidiaries of major companies. A number of these companies are privately owned and have grown mainly by reinvesting the profits. Examples are Bachem, Switzerland; Dishman, India; F.I.S. and Poli Industria Chimica, Italy; Hikal, India, and Hovione, Portugal. Customers prefer to do business with mid-sized companies, because communications are easier — they typically deal directly with the decision maker — and they can better leverage their purchasing power. The third tier includes thousands of small independents, with sales below $100 million per year. Most of them are located in Asia. They often specialize in niche technologies. The minimum economical size of a fine chemical company depends on the availability of infrastructure. If a company is located in an industrial park, where analytical services, utilities, safety, health, and environmental (SHE) services, and warehousing are readily available, there is practically no lower limit. New fine chemical plants have appeared mostly in Far East countries over the past few years. Their annual turnover rate rarely exceeds $25 million. All big and medium-size fine chemical companies have cGMP-compliant plants that are suitable for the production of pharmaceutical fine chemicals.
Autologous fat (fat tissue transferred from elsewhere in the body). Teflon. Bovine glutaraldehyde cross-linked collagen (collagen from cows). Carbon-coated zirconium/graphite beads ("Durasphere"). Polydimethylsiloxane elastomer (silicone) biomaterial implants ("PTQ implant"). Dextranomer in non-animal stabilised hyaluronic acid ("Solesta", "NASHA Dx"). Hydrogel cross-linked with polyacrylamide ("Bulkamid"). Porcine dermal collagen (collagen from pig skin, "Permacol"). Synthetic calcium hydroxylapatite ceramic microspheres. Polyacrylonitrile in cylinder form. aluminum potassium sulfate and tannic acid (ALTA).
== History == The first description of phenylalanine was made in 1879, when Schulze and Barbieri identified a compound with the empirical formula, C9H11NO2, in yellow lupine (Lupinus luteus) seedlings. In 1882, Erlenmeyer and Lipp first synthesized phenylalanine from phenylacetaldehyde, hydrogen cyanide, and ammonia. The genetic codon for phenylalanine was first discovered by J. Heinrich Matthaei and Marshall W. Nirenberg in 1961. They showed that by using mRNA to insert multiple uracil repeats into the genome of the bacterium E. coli, they could cause the bacterium to produce a polypeptide consisting solely of repeated phenylalanine amino acids. This discovery helped to establish the nature of the coding relationship that links information stored in genomic nucleic acid with protein expression in the living cell.
It was part of a series of twenty performances titled Hellfest from Home, recorded shortly before at the festival site in Clisson, France. That same month, Hangman's Chair were part of the lineup for the second and final edition of the online metal music festival Slay at Home, organised by Frank Godla, co-owner of Metal Injection. Slay at Home aimed to raise funds for MusiCares, the Cancer Research Institute, the Iggy Fund and the National Alliance on Mental Illness. In early October 2021, the band released the single "Loner" with a music video. Another single titled "An Ode To Breakdown" followed in November, accompanied by a live video taken from the at-home edition of Hellfest. During the recording sessions for their upcoming album, Hangman's Chair had set aside two songs, including "Judge Penitent". It was released as a single at the beginning of December and became the theme music for the fifth season (2021) of Gang Stories, a Deezer-produced podcast narrated by NTM rapper JoeyStarr.
Sources: en.wikipedia.org
In June 2022, FCC Commissioner Brendan Carr called for Google and Apple to remove TikTok from their app stores, saying sensitive data were being accessed from Beijing and ByteDance would be "required by law to comply with [Chinese government] surveillance demands." In November 2022, Christopher A. Wray, director of the Federal Bureau of Investigation (FBI), said the Chinese government could use TikTok for influence operations on its users. In May 2023, a former ByteDance employee filed a wrongful termination lawsuit alleging that Hong Kong users' device information and communications, particularly those of demonstrators in the 2019–2020 Hong Kong protests, were accessed by Chinese Communist Party members in 2018. ByteDance denied the claims, saying the employee worked on a defunct project and that TikTok was pulled out of Hong Kong in 2020. The whistleblower claimed in a sworn court statement that his father in mainland China had been detained by the authorities in retaliation for his speaking to the media about alleged censorship by TikTok. In June 2023, TikTok confirmed that some financial information, such as tax forms and Social Security numbers, of American content creators are stored in China. This applies to those signing contracts with and receiving payment transactions from ByteDance. Whether similar information will remain exempt from being treated as "protected user data" is being negotiated with Committee on Foreign Investment in the United States (CFIUS).
=== Category:EC 3.1 (act on ester bonds) === Nuclease Endonuclease Exonuclease Category:EC 3.1.1 Acid hydrolase Phospholipase A (EC 3.1.1.4) Acetylcholinesterase (EC 3.1.1.7) Cholinesterase (EC 3.1.1.8) Lipoprotein lipase (EC 3.1.1.34) Category:EC 3.1.2 Ubiquitin carboxy-terminal hydrolase L1 (EC 3.1.2.15) Category:EC 3.1.3 Phosphatase Alkaline phosphatase (EC 3.1.3.1) Fructose bisphosphatase (EC 3.1.3.11) Category:EC 3.1.4 Phospholipase C (EC 3.1.4.3) CGMP specific phosphodiesterase type 5 (EC 3.1.4.17) Phospholipase D (EC 3.1.4.50) (3-methyl-2-oxobutanoate dehydrogenase (2-methylpropanoyl-transferring))-phosphatase Category:EC 3.1.21 Restriction enzyme Type 1 (EC 3.1.21.3) Restriction enzyme Type 2 (EC 3.1.21.4) Restriction enzyme Type 3 (EC 3.1.21.5) Restriction enzyme Type 4 (?) Deoxyribonuclease I (EC 3.1.21.1) Category:EC 3.1.26 RNase H (EC 3.1.26.4) Category:EC 3.1.27 Ribonuclease
=== Commemorations === Oregon State University completed construction of the $77 million, 100,000-square-foot (9,300 m2) Linus Pauling Science Center in the late 2000s, now housing the bulk of Oregon State's chemistry classrooms, labs, and instruments. On March 6, 2008, the United States Postal Service released a 41 cent stamp honoring Pauling designed by artist Victor Stabin. His description reads: "A remarkably versatile scientist, structural chemist Linus Pauling (1901–1994) won the 1954 Nobel Prize in Chemistry for determining the nature of the chemical bond linking atoms into molecules. His work in establishing the field of molecular biology; his studies of hemoglobin led to the classification of sickle cell anemia as a molecular disease." The other scientists on this sheet of stamps included Gerty Cori, biochemist, Edwin Hubble, astronomer, and John Bardeen, physicist. California Governor Arnold Schwarzenegger and First Lady Maria Shriver announced on May 28, 2008, that Pauling would be inducted into the California Hall of Fame, located at The California Museum for History, Women and the Arts. The induction ceremony took place December 15, 2008. Pauling's son Linus Jr. was asked to accept the honor in his place. By proclamation of Gov. John Kitzhaber in the state of Oregon, February 28 has been named "Linus Pauling Day". The Linus Pauling Institute still exists, but moved in 1996 from Palo Alto, California, to Corvallis, Oregon, where it is part of the Linus Pauling Science Center at Oregon State University.
Even though as of March 2025 they still pushed for buyout in July they abandoned the bid. On March 6, 2025, 7-Eleven's parent company Seven & I Holdings announced that it would spin off the US store operations into its own publicly traded entity by the end of 2026, following the announcement of the appointment of its first foreign CEO Stephen Hayes Dacus.
Accordingly, although personal expressions of religious faith were not explicitly banned, a strong sense of social stigma was imposed on them by the formal structures and mass media, and it was generally considered unacceptable for members of certain professions (teachers, state bureaucrats, soldiers) to be openly religious. While persecution accelerated following Stalin's rise to power, a revival of Orthodoxy was fostered by the government during World War II and the Soviet authorities sought to control the Russian Orthodox Church rather than liquidate it. During the first five years of Soviet power, the Bolsheviks executed 28 Russian Orthodox bishops and over 1,200 Russian Orthodox priests. Many others were imprisoned or exiled. Believers were harassed and persecuted. Most seminaries were closed, and the publication of most religious material was prohibited. By 1941, only 500 churches remained open out of about 54,000 in existence before World War I. Convinced that religious anti-Sovietism had become a thing of the past, and with the looming threat of war, the Stalin administration began shifting to a more moderate religion policy in the late 1930s. Soviet religious establishments overwhelmingly rallied to support the war effort during World War II. Amid other accommodations to religious faith after the German invasion, churches were reopened. Radio Moscow began broadcasting a religious hour, and a historic meeting between Stalin and Orthodox Church leader Patriarch Sergius of Moscow was held in 1943.
Sources: en.wikipedia.org
Late complications may result in the development of pigmented gallstones, which is secondary to the detritus of the broken-down blood cells (unconjugated or indirect bilirubin) accumulating within the gallbladder. Also, patients who are heterozygous for a hemochromatosis gene may exhibit iron overload, despite the hemochromatosis genes being recessive. In chronic patients, an infection or other illness can cause an increase in the destruction of red blood cells, resulting in the appearance of acute symptoms – a hemolytic crisis. On a blood smear, Howell-Jolly bodies may be seen within red blood cells. Primary treatment for patients with symptomatic HS has been total splenectomy, which eliminates the hemolytic process, allowing for normal hemoglobin, reticulocyte and bilirubin levels. The resultant asplenic patient is susceptible to encapsulated bacterial infections, the risk of which can be reduced with vaccination. If other symptoms such as abdominal pain persist, the removal of the gallbladder may be warranted for symptomatic cholelithiasis.
== Sweetness properties == On a weight basis, brazzein is 500 to 2000 times sweeter than sucrose, compared to 10% sucrose and 2% sucrose solution respectively. Its sweet perception is more similar to sucrose than that of thaumatin, with a clean sweet taste, lingering aftertaste, and slight delay (longer than aspartame) in an equi-sweet solution. Brazzein is stable over a broad pH range from 2.5 to 8, and is heat stable at 98 °C (208 °F) for 2 hours.
Most bat species are polygynous, where males mate with multiple females. Male pipistrelle, noctule, and vampire bats may claim and defend resources that attract females, such as roost sites, and mate with those females. Males unable to claim a site are forced to live on the periphery, where they have less reproductive success. Promiscuity, where both sexes mate with multiple partners, exists in species like the Mexican free-tailed bat and the little brown bat. There appears to be bias towards certain males among females in these bats. In a few species, such as the yellow-winged bat (Lavia frons) and spectral bat, adult males and females form monogamous pairs. Lek mating, where males aggregate and compete for female choice through display, is rare in bats but occurs in the hammerheaded bat. Temperate-living bats typically mate during late summer and autumn, while tropical bats may mate multiple times a year. In hibernating species, males will copulate with females in torpor. Female bats use a variety of strategies to control the timing of pregnancy and birth, to make delivery coincide with maximum food availability and other ecological factors. Females of some species use delayed fertilisation, in which mating occurs in late summer to early autumn, but sperm is stored in the reproductive tract, delaying fertilisation until the following late winter to early spring. Other species exhibit delayed implantation, in which the egg is fertilised after mating but does not experience all its cell divisions until external conditions become favourable.
== Corneal cross-linking == In 2002, Hafezi's clinical and research interests turned to the cornea. He became a corneal specialist, and his work helped develop the principles of corneal collagen cross-linking (CXL) and translate CXL from a laboratory into a clinical setting, initially for the treatment of keratoconus. Hafezi's combination of basic science knowledge combined with clinical, surgical experience of CXL has led him to become one of the world's leading experts on both keratoconus and cross-linking technology. The impact of CXL on the treatment of keratoconus is hard to underestimate: today, CXL considered to be the treatment of choice for progressive keratoconus and corneal ectasias, reducing the need for corneal transplantation by half. Hafezi continued to work to expand the number of people who could benefit from CXL. Briefly, the original CXL method, termed the Dresden Protocol, involves removing the central 8–10 mm of the corneal epithelium of adult patients with corneas thicker than 400 μm, and applying 0.1% riboflavin solution to the cornea for 30 minutes before, and at 5-minute intervals during 365 nm UV-A irradiation of the corneal surface at an irradiance of 3 mW/cm2. Hafezi has helped push the boundaries, pioneering CXL in children with keratoconus, the use of hypoosmolar riboflavin solutions to treat people with thin (≤400 μm) corneas. and using CXL to treat post-LASIK ectasia. The knowledge Hafezi accrued from this work led to him becoming a leading international expert on corneal ectasia in general and keratoconus in particular.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.